MA49378A - Méthode de traitement de la thrombocytopénie immunitaire - Google Patents

Méthode de traitement de la thrombocytopénie immunitaire

Info

Publication number
MA49378A
MA49378A MA049378A MA49378A MA49378A MA 49378 A MA49378 A MA 49378A MA 049378 A MA049378 A MA 049378A MA 49378 A MA49378 A MA 49378A MA 49378 A MA49378 A MA 49378A
Authority
MA
Morocco
Prior art keywords
treatment
immune thrombocytopenia
thrombocytopenia
immune
Prior art date
Application number
MA049378A
Other languages
English (en)
Inventor
Claus Peter Kiessling
Grant Langdon
Rocio Lledo-Garcia
Ute Massow
Rose Gunter Snipes
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1709554.8A external-priority patent/GB201709554D0/en
Priority claimed from GBGB1718589.3A external-priority patent/GB201718589D0/en
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of MA49378A publication Critical patent/MA49378A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA049378A 2017-06-15 2018-06-15 Méthode de traitement de la thrombocytopénie immunitaire MA49378A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1709554.8A GB201709554D0 (en) 2017-06-15 2017-06-15 Method of treatment
GBGB1718589.3A GB201718589D0 (en) 2017-11-10 2017-11-10 Method of treatment

Publications (1)

Publication Number Publication Date
MA49378A true MA49378A (fr) 2020-04-22

Family

ID=62684788

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049378A MA49378A (fr) 2017-06-15 2018-06-15 Méthode de traitement de la thrombocytopénie immunitaire

Country Status (16)

Country Link
US (1) US20200140548A1 (fr)
EP (1) EP3638305A1 (fr)
JP (1) JP2020523419A (fr)
KR (1) KR20200018643A (fr)
CN (1) CN110785186A (fr)
AU (1) AU2018285577A1 (fr)
BR (1) BR112019026694A2 (fr)
CA (1) CA3066298A1 (fr)
CL (1) CL2019003673A1 (fr)
CO (1) CO2019014525A2 (fr)
IL (1) IL271248A (fr)
MA (1) MA49378A (fr)
MX (1) MX2019015065A (fr)
RU (1) RU2020100880A (fr)
SG (1) SG11201911832PA (fr)
WO (1) WO2018229249A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007087289A2 (fr) * 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York ANTICORPS ANTI-FcRn UTILISÉS DANS LE TRAITEMENT D'ÉTATS AUTO/ALLO-IMMUNS
TWI593423B (zh) * 2008-04-25 2017-08-01 戴埃克斯有限公司 Ｆｃ受體結合蛋白
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
FI3137504T3 (fi) * 2014-04-30 2023-08-07 Hanall Biopharma Co Ltd Fcrn:ään sitoutuva vasta-aine autoimmuunisairauksien hoitamista varten
FI3250610T3 (fi) * 2015-01-30 2023-11-01 Momenta Pharmaceuticals Inc Fcrn-vasta-aineita ja menetelmiä niiden käyttämiseksi
GB201508180D0 (en) * 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies

Also Published As

Publication number Publication date
RU2020100880A (ru) 2021-07-15
WO2018229249A1 (fr) 2018-12-20
EP3638305A1 (fr) 2020-04-22
KR20200018643A (ko) 2020-02-19
AU2018285577A1 (en) 2020-01-30
RU2020100880A3 (fr) 2021-11-10
JP2020523419A (ja) 2020-08-06
CA3066298A1 (fr) 2018-12-20
US20200140548A1 (en) 2020-05-07
SG11201911832PA (en) 2020-01-30
BR112019026694A2 (pt) 2020-06-23
CL2019003673A1 (es) 2020-07-17
CN110785186A (zh) 2020-02-11
IL271248A (en) 2020-01-30
MX2019015065A (es) 2020-08-03
CO2019014525A2 (es) 2020-04-24

Similar Documents

Publication Publication Date Title
MA46771A (fr) Méthode de traitement de tumeur immunothérapeutique
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA52371A (fr) Méthodes de traitement d'infections dues aux coronaviridae
MA43190A (fr) Traitement de la dyslipidémie mixte
MA50264A (fr) Méthodes de traitement des infections de type hépatite b
CL2018000728A1 (es) Anticuerpos anti-cd19 humano humanizados y métodos de utilización
DK3777855T3 (da) Fremgangsmåder til behandling af fibrotiske sygdomme
MA48996A (fr) Méthodes de traitement de maladies neurodégénératives
MA40498A (fr) Méthode de traitement de l'intoxication par organophosphates
MA47820A (fr) Traitement de la glycogénose de type iii
MA41462A (fr) Méthode de traitement de maladies
MA48862A (fr) Méthode de traitement de tumeur immunothérapeutique
MA52216A (fr) Méthodes de traitement de la colite ulcéreuse
DK3453721T3 (da) Process of manufacture of annexin v
EP3684342C0 (fr) Procédé de traitement
FR3039368B1 (fr) Procede de traitement cosmetique
IT201700028116A1 (it) Gruppo di attuazione rotativo-lineare
GB201706406D0 (en) Method of treatment
MA51525A (fr) Traitement de minéraux
FR3034011B1 (fr) Procede de traitement cosmetique des cheveux
MA41636A (fr) Méthode de traitement de la cholangite sclérosante primitive
GB201815588D0 (en) Method of treatment
MA56033A (fr) Méthodes de traitement de la sclérodermie généralisée
MA45245A (fr) Méthode de traitement de maladie intestinale inflammatoire
MA49378A (fr) Méthode de traitement de la thrombocytopénie immunitaire